Outcomes of switching from protease inhibitor-based antiretroviral therapy to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in virologically suppressed adults with nucleos(t)ide analogue resistance– a phase IV randomised, open-label study (PIBIK study)
| Title: | Outcomes of switching from protease inhibitor-based antiretroviral therapy to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in virologically suppressed adults with nucleos(t)ide analogue resistance– a phase IV randomised, open-label study (PIBIK study) |
|---|---|
| Authors: | Iwuji, CollinsAff1, Aff2, IDs12985025026483_cor1; Waters, LauraAff3; Milinkovic, AnaAff4; Orkin, ChloeAff5, Aff6; Fox, JulieAff7; Post, FrankAff8; Perry, NickyAff9; Bruce, ChloeAff10; Dailey, NatalieAff10; To, YeAff10; Bremner, StephenAff10, Aff11; Churchill, DuncanAff9; Geretti, Anna MariaAff12, Aff13, Aff14 |
| Source: | Virology Journal. 22(1) |
| Database: | Springer Nature Journals |